Literature DB >> 23933765

Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis.

D Teschner1, E Distler1, D Wehler1, M Frey1, D Marandiuc2, K Langeveld3, M Theobald1, S Thomas1, W Herr4.   

Abstract

Depletion of naive T cells from donor leukapheresis products (LPs) aims at the reduction of alloreactivity, while preserving memory T-cell reactivity (for example, to pathogens). This study established the immunomagnetic depletion procedure under clean room conditions using CD45RA beads and analyzed LPs of six donors for cell composition and functional immune responses. CD45RA depletion resulted in 3.4-4.7 log (median 4.4) reduction of CD45RA(+) T cells, thereby eliminating naive and late effector T cells. B cells were also completely removed, whereas significant proportions of NK cells, monocytes and granulocytes persisted. CD45RA-depleted LPs contained effector and central memory CD4(+) and CD8(+) T cells that showed sustained IFN-γ secretion to CMV, EBV, Aspergillus and Candida Ags. Alloreactivity was measured in MLRs between donors with complete HLA-mismatch. Alloreactive CD8(+) T cells were strongly reduced (median >1-log) upon CD45RA depletion, whereas alloreactive CD4(+) T cells persisted in significant numbers. In conclusion, clinical grade depletion of CD45RA(+) naive T cells from donor LPs is feasible and highly efficient. The depleted products show sustained CD4(+) and CD8(+) T-cell reactivity to pathogens and effectively reduced CD8-mediated alloreactivity. Prophylactic and preemptive infusions after allogeneic SCT may improve T-cell reconstitution and pathogen-specific immunosurveillance, along with lower risk of inducing GVHD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23933765     DOI: 10.1038/bmt.2013.114

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  25 in total

1.  Flexibility in MHC and TCR recognition: degenerate specificity at the T cell level in the recognition of promiscuous Th epitopes exhibiting no primary sequence homology.

Authors:  S K Joshi; P R Suresh; V S Chauhan
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

Review 2.  The putative mechanism of the immunomodulating effect of HLA-DR shared allogeneic blood transfusions on the alloimmune response.

Authors:  Marloes M Waanders; Dave L Roelen; Anneke Brand; Frans H J Claas
Journal:  Transfus Med Rev       Date:  2005-10

Review 3.  Allogeneic memory T cell response.

Authors:  Benny J Chen
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

4.  IL-21-treated naive CD45RA+ CD8+ T cells represent a reliable source for producing leukemia-reactive cytotoxic T lymphocytes with high proliferative potential and early differentiation phenotype.

Authors:  Jana Albrecht; Michaela Frey; Daniel Teschner; Alexander Carbol; Matthias Theobald; Wolfgang Herr; Eva Distler
Journal:  Cancer Immunol Immunother       Date:  2010-11-03       Impact factor: 6.968

Review 5.  Peptide vaccine therapy for leukemia.

Authors:  K Rezvani
Journal:  Int J Hematol       Date:  2011-03-08       Impact factor: 2.490

Review 6.  Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update.

Authors:  Ruth Seggewiss; Hermann Einsele
Journal:  Blood       Date:  2010-03-09       Impact factor: 22.113

7.  Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.

Authors:  Tobias Feuchtinger; Kathrin Opherk; Wolfgang A Bethge; Max S Topp; Friedhelm R Schuster; Eva M Weissinger; Mohamad Mohty; Reuven Or; Michael Maschan; Michael Schumm; Klaus Hamprecht; Rupert Handgretinger; Peter Lang; Hermann Einsele
Journal:  Blood       Date:  2010-07-12       Impact factor: 22.113

8.  Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion.

Authors:  Petra Hoffmann; Ruediger Eder; Tina J Boeld; Kristina Doser; Biserka Piseshka; Reinhard Andreesen; Matthias Edinger
Journal:  Blood       Date:  2006-08-17       Impact factor: 22.113

9.  Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.

Authors:  Marion Nonn; Wolfgang Herr; Shamsul Khan; Mariya Todorova; Irina Link; Jochen Thies; Eva Distler; Marcus Kaltwasser; Julia Hoffmann; Christoph Huber; Udo F Hartwig
Journal:  Transplantation       Date:  2008-11-27       Impact factor: 4.939

10.  High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.

Authors:  M J Pittet; D Valmori; P R Dunbar; D E Speiser; D Liénard; F Lejeune; K Fleischhauer; V Cerundolo; J C Cerottini; P Romero
Journal:  J Exp Med       Date:  1999-09-06       Impact factor: 14.307

View more
  31 in total

Review 1.  How do I perform hematopoietic progenitor cell selection?

Authors:  Scott T Avecilla; Cheryl Goss; Sharon Bleau; Jo-Ann Tonon; Richard C Meagher
Journal:  Transfusion       Date:  2016-02-25       Impact factor: 3.157

2.  Generation of memory T cells for adoptive transfer using clinical-grade anti-CD62L magnetic beads.

Authors:  S Verfuerth; P S E Sousa; L Beloki; M Murray; M D Peters; A T O'Neill; S Mackinnon; M W Lowdell; R Chakraverty; E R Samuel
Journal:  Bone Marrow Transplant       Date:  2015-06-15       Impact factor: 5.483

3.  Engineering haploidentical transplants.

Authors:  S Naik; H E Heslop
Journal:  Bone Marrow Transplant       Date:  2015-05-11       Impact factor: 5.483

4.  Selective, efficient modulation of activated CD4+ αβT cells by the novel humanized antibody GZ-αβTCR targeting human αβTCR.

Authors:  G Blank; C Welker; J Haarer; M Sterk; S Nadalin; V A C Yañez; T O Joos; A Menrad; D Snell; G LaCorcia; A Königsrainer; R Handgretinger; K Schilbach
Journal:  Bone Marrow Transplant       Date:  2014-11-17       Impact factor: 5.483

5.  Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared with CD3-targeted T-cell depletion.

Authors:  Brandon M Triplett; Brad Muller; Guolian Kang; Ying Li; Shane J Cross; Joseph Moen; Lea Cunningham; William Janssen; Ewelina Mamcarz; David R Shook; Ashok Srinivasan; John Choi; Randall T Hayden; Wing Leung
Journal:  Transpl Infect Dis       Date:  2018-01-16       Impact factor: 2.228

Review 6.  Prevention and Treatment of Acute Graft-versus-Host Disease in Children, Adolescents, and Young Adults.

Authors:  Erin Gatza; Pavan Reddy; Sung Won Choi
Journal:  Biol Blood Marrow Transplant       Date:  2020-01-11       Impact factor: 5.742

7.  Targeting polo-like kinase 1 suppresses essential functions of alloreactive T cells.

Authors:  Carsten Berges; Manik Chatterjee; Max S Topp; Hermann Einsele
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

8.  The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects.

Authors:  Hidekazu Itamura; Takero Shindo; Isao Tawara; Yasushi Kubota; Ryusho Kariya; Seiji Okada; Krishna V Komanduri; Shinya Kimura
Journal:  JCI Insight       Date:  2016-07-07

9.  Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity.

Authors:  Dongrui Wang; Brenda Aguilar; Renate Starr; Darya Alizadeh; Alfonso Brito; Aniee Sarkissian; Julie R Ostberg; Stephen J Forman; Christine E Brown
Journal:  JCI Insight       Date:  2018-05-17

10.  Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in a Patient with Chronic Granulomatous Disease and Active Infection: A First Report.

Authors:  Mark Parta; Dianne Hilligoss; Corin Kelly; Nana Kwatemaa; Narda Theobald; Harry Malech; Elizabeth M Kang
Journal:  J Clin Immunol       Date:  2015-10-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.